Skip to content
value.today

Pasithea Therapeutics Corp.

🇺🇸 Miami Beach, Florida, USAHealth CareFounded 2020
Total raised
$32 M
2 rounds on record
Latest round
$30 M
Nov 2021
First round on record
Jan 2021
Today
Went public
See the company page

Pasithea Therapeutics Corp. is listed today as Pasithea Therapeutics Corp.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pasithea Therapeutics Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$30 MNo. 2$10 to $50 million

Pasithea Therapeutics Corp.: Raise no. 2, Nov 2021

Investors in this round

21 investors had bought by the notice of Dec 7, 2021: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,734,200
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stanley M. Gloss · Executive Officer
  • Tiago Andre Dos Reis Marques · Executive Officer, Director
  • Yassine Bendiabdallah · Executive Officer, Director
  • Emer Dos Reis Leahy · Director
  • Lawrence Steinman · Director
  • Simon Dumesnil · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • EF Hutton, division of Benchmark Investments, LLC (CRD 103792) · New York, New YorkSold in CA, CT, FL, NJ, NV, NY, PR

Remarks in the notice

  • On fees: “EF Hutton also received a cash fee equal to 1.0% of the gross proceeds raised by the Company in the Offering for non-accountable expenses, and $70,000 for accountable expenses.”
  • On the amounts: “The securities were issued in an offering of 8,680,000 shares and 8,680,000 warrants issued as part of a PIPE transaction, for $3.50 per share and accompanying warrant.”

Signed by Tiago Reis Marques, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 7, 2021. Read the notice at the SEC.

equity, optionsSEC
Jan 2021$1 MNo. 1Under $2 million

Pasithea Therapeutics Corp.: Raise no. 1, Jan 2021

Investors in this round

30 investors had bought by the notice of Mar 19, 2021: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Craig Maxx Auringer · Executive Officer, Director
  • Israel Maxx Abramowitz · Executive Officer, Director
  • Lawrence Reis Steinman · Director
  • Tiago Reis Marques · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Israel Maxx Abramowitz, Coo. Source: SEC Form D, newest notice filed Mar 19, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pasithea Therapeutics Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2021).

    SEC Form D · Dec 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2021

That is all the official record says: Pasithea Therapeutics Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pasithea Therapeutics Corp. are on record.

Investors#

No investor of Pasithea Therapeutics Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 30 investors.

Largest shareholders today

Institutions holding Pasithea Therapeutics Corp. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pasithea Therapeutics Corp.
NameRoleNamed in
Stanley M. GlossExecutive officerDec 2021
Tiago Andre Dos Reis MarquesExecutive officerDec 2021
Yassine BendiabdallahExecutive officerDec 2021
Craig Maxx AuringerExecutive officerMar 2021
Israel Maxx AbramowitzExecutive officerMar 2021
Emer Dos Reis LeahyDirectorDec 2021
Lawrence SteinmanDirectorDec 2021
Simon DumesnilDirectorDec 2021
Tiago Andre Dos Reis MarquesDirectorDec 2021
Yassine BendiabdallahDirectorDec 2021
Craig Maxx AuringerDirectorMar 2021
Israel Maxx AbramowitzDirectorMar 2021
Lawrence Reis SteinmanDirectorMar 2021
Tiago Reis MarquesDirectorMar 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.